By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB have extended a collaboration aimed at identifying multiple targets in the drug discovery process, Emerald announced on Thursday.

The three-year extension provides the company with research funding, it said. The Bainbridge Island, Wash.-based firm also is eligible for milestone payments and royalties on future drug product revenues.

Additional financial and other details of the deal were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.